Immunogenicity of biologic agents in rheumatoid arthritis patients: Lessons for clinical practice

Rheumatology (United Kingdom)

Volumn 55, Issue 2, 2015, Pages 210-220

  Schaeverbeke, Thierry ^a,b   Truchetet, Marie Elise ^a,c   Kostine, Marie ^a   Barnetche, Thomas ^a   Bannwarth, Bernard ^a,d   Richez, Christophe ^a,c  

^a HÔPITAL PELLEGRIN   (France)

^b Univ Victor Segalen Bordeaux 2   (France)

^c CNRS Bordeaux Segalen University   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Adalimumab; Anti drug antibody; Anti TNF; Biodrug; Biologic agents; Etanercept; Immunogenicity; Infliximab; Methotrexate; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL PRODUCT; CORTICOSTEROID; DRUG ANTIBODY; METHOTREXATE;

ANTIBODY DETECTION; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; HUMAN; IMMUNOGENICITY; INFLAMMATION; OBESITY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT;

EID: 84961907147     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev277     Document Type: Review

References (67)

1. Van Vollenhoven RF, Klareskog L. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. Scand J Rheumatol 2007;36:418-23.
2. Hetland ML, Christensen IJ, Tarp U et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
3. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti_tumor necrosis factor a agent to a second anti-tumor necrosis factor a agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
4. Van Vollenhoven R. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
5. Wick MC, Ernestam S, Lindblad S et al. Adalimumab (Humira_) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade_) or etanercept (Enbrel_): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005;34:353-8.
6. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004;251(Suppl 2):II/4_II/9.
7. Elliott MJ, Maini RN, Feldmann M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
8. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with lowdose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
9. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfá E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010;38:82-9.
10. van Schouwenburg PA, van de Stadt LA, de Jong RN et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013;72:104-9.
11. Pan Y, Yuhasz SC, Amzel LM. Anti-idiotypic antibodies:biological function and structural studies. FASEB J 1995;9:43-9.
12. Vincent FB, Morand EF, Murphy K et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.
13. Nash P, Nayiager S, Genovese MC et al. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res 2013;65:718-28.
14. Radstake TRDJ, Svenson M, Eijsbouts AM et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45.
15. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Antiinfliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and antitumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21.
16. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947-55.
17. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006;33:31-6.
18. Finckh A, Dudler J, Wermelinger F et al. Influence of antiinfliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine 2010;77:313-8.
19. Bartelds GM, Krieckaert CLM, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
20. Ducourau E, Mulleman D, Paintaud G et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011;13:R105.
21. Pascual-Salcedo D, Plasencia C, Ramiro S et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50:1445-52.
22. Krintel SB, Grunert VP, Hetland ML et al. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology 2013;52:1245-53.
23. Smolen J, Landewe RB, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804.
24. Stubenrauch K, Wessels U, Vogel R, Schleypen J. Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards. Anal Biochem 2009;390:189-96.
25. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007;46:1828-34.
26. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Clinical response to adalimumab: relationship to antiadalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6.
27. Bendtzen K, Geborek P, Svenson M et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782-9.
28. van Schouwenburg PA, Rispens T. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9:164-72.
29. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti_tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
30. Bender NK, Heilig CE, Dröll B et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007;27:269-74.
31. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Antiinfliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis 2010;69:1-17.
32. Dore RK, Mathews S, Schechtman J et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25:40-6.
33. Keystone EC, Schiff MH, Kremer JM et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63.
34. Klareskog L, Gaubitz M, Rodriguez-Valverde V et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:238-47.
35. Haggerty HG, Abbott MA, Reilly TP et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol 2007;34:2365-73.
36. Genovese MC, Covarrubias A, Leon G et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63:2854-64.
37. Rispens T, de Vrieze H, de Groot E et al. Antibodies to constant domains of therapeutic monoclonal antibodies:anti-hinge antibodies in immunogenicity testing. J Immunol Methods 2012;375:93-9.
38. Emery P, Fleischmann RM, Moreland LW et al. Golimumab, a human anti-tumor necrosis factor a monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebocontrolled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
39. Keystone EC, Genovese MC, Hall S et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol 2013;40:1097-103.
40. Choy E, McKenna F, Vencovský J et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology 2012;51:1226-34.
41. Fleischmann R, Vencovsky J, Van Vollenhoven RF et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy:the FAST4WARD study. Ann Rheum Dis 2009;68:805-11.
42. Stubenrauch K, Wessels U, Birnboeck H et al. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010;32:1597-609.
43. Ogata A, Tanimura K, Sugimoto T et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res 2014;66:344-54.
44. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment:results of a phase IIB randomized, double-blind, placebocontrolled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
45. Mease PJ, Cohen S, Gaylis NB et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE Trial. J Rheumatol 2010;37:917-27.
46. van Schouwenburg PA, Bartelds GM, Hart MH et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals ''hidden'' immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010;362:82-8.
47. van Schouwenburg PA, Krieckaert CL, Rispens T et al. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 2013;72:1680-6.
48. Wolbink GJ, Voskuyl AE, Lems WF et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7.
49. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012;71:1914-5.
50. Kurnik K, Bidlingmaier C, Engl W et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010;16:256-62.
51. Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/ FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients-long-term follow-up and continuing experience. Haemophilia 2012;18:e18_20.
52. Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions:systematic review and meta-analysis. JAMA 2013;173:1416-28.
53. Cutolo M, Seriolo B, Pizzorni C et al. Use of glucocorticoids and risk of infections. Autoimmun Rev 2008;8:153-5.
54. Pradeu T, Jaeger S, Vivier E. The speed of change: towards a discontinuity theory of immunity? Nat Rev Immunol 2013;13:764-9.
55. Gremese E, Carletto A, Padovan M et al. Obesity and reduction of the response rate to anti-tumor necrosis factor a in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res 2013;65:94-100.
56. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a metaanalysis. Am J Gastroenterol 2013;108:40-7.
57. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542.
58. Ong DEH, Kamm MA, Hartono JL, Lust M. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy. J Gastroenterol Hepatol 2013;28:1595-9.
59. Kneepkens EL, Wei JC-C, Nurmohamed MT et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis 2015;74:396-401.
60. Plasencia C, Pascual-Salcedo D, García-Carazo S et al. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res Ther 2013;15:R79.
61. Ternant D, Mulleman D, Lauféron F et al. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol 2012;73:55-65.
62. Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol 2014;170:261-73.
63. Adişen E, Aral A, Aybay C, Gürer MA. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study. J Dermatol 2010;37:708-13.
64. Lecluse LLA, Driessen RJB, Spuls PI et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010;146:127-32.
65. Garcês S, Antunes M, Benito-Garcia E et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2014;73:1138-43.
66. Mulleman D, Chu Miow Lin D, Ducourau E et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit 2010;32:232-6.
67. Krieckaert CL, Jamnitski A, Nurmohamed MT et al. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012;64:3850-5.